Overview

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

Status:
Not yet recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.

Phase:

Phase 2

Details

Lead Sponsor:

Western Sydney Local Health District

Collaborators:

Deakin University
Monash University
Royal Perth Hospital
The University of Queensland
University of Melbourne
University of Sydney

Treatments:

Acetylcysteine